A pilot study of the association of low plasma adiponectin and Barrett's esophagus

American Journal of Gastroenterology

Volumn 103, Issue 6, 2008, Pages 1358-1364

  Rubenstein, Joel H ^a,b,e   Dahlkemper, Anne ^b   Kao, John Y ^b   Zhang, Min ^b   Morgenstern, Hal ^c   McMahon, Laurence ^a,b   Inadomi, John M ^d  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ABDOMINAL OBESITY; ADIPOSE TISSUE CELL; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BARRETT ESOPHAGUS; BLOOD SAMPLING; BODY MASS; CIGARETTE SMOKING; CIRCULATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; DISEASE DURATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADIPONECTIN; BARRETT ESOPHAGUS; BODY MASS INDEX; CASE-CONTROL STUDIES; COHORT STUDIES; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; REGRESSION ANALYSIS; RISK FACTORS; SEX FACTORS;

EID: 44949121499     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01823.x     Document Type: Article

References (38)

1. El-Serag HB, Mason AC, Petersen N, et al. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 2002 50 : 368 72.
2. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999 340 : 825 31.
3. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 2002 97 : 1888 95.
4. Portale G, Peters JH, Hagen JA, et al. Comparison of the clinical and histological characteristics and survival of distal esophageal-gastroesophageal junction adenocarcinoma in patients with and without Barrett mucosa. Arch Surg 2005 140 : 570 4.
5. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005 143 : 199 211.
6. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005 3 : 1 10.
7. La Vecchia C, Negri E, Lagiou P, et al. Oesophageal adenocarcinoma: A paradigm of mechanical carcinogenesis? Int J Cancer 2002 102 : 269 70.
8. Lagergren J. Controversies surrounding body mass, reflux, and risk of oesophageal adenocarcinoma. Lancet Oncol 2006 7 : 347 9.
9. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007 133 : 34 41 quiz 311.
10. El-Serag HB, Kvapil P, Hacken-Bitar J, et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005 100 : 2151 6.
11. Edelstein ZR, Farrow DC, Bronner MP, et al. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007 133 : 403 11.
12. Chen SC, Chou CK, Wong FH, et al. Overexpression of epidermal growth factor and insulin-like growth factor-I receptors and autocrine stimulation in human esophageal carcinoma cells. Cancer Res 1991 51 : 1898 903.
13. Liu YC, Leu CM, Wong FH, et al. Autocrine stimulation by insulin-like growth factor I is involved in the growth, tumorigenicity and chemoresistance of human esophageal carcinoma cells. J Biomed Sci 2002 9 : 665 74.
14. Festa A, D'Agostino R Jr., Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes 2002 51 : 1131 7.
15. Somasundar P, Riggs D, Jackson B, et al. Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am J Surg 2003 186 : 575 8.
16. Stattin P, Lukanova A, Biessy C, et al. Obesity and colon cancer: Does leptin provide a link? Int J Cancer 2004 109 : 149 52.
17. de Martel C, Haggerty TD, Corley DA, et al. Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. Am J Gastroenterol 2007 102 : 1166 72.
18. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: A systematic review. Br J Cancer 2006 94 : 1221 5.
19. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999 257 : 79 83.
20. Yildiz BO, Suchard MA, Wong ML, et al. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A 2004 101 : 10434 9.
21. Shea SA, Hilton MF, Orlova C, et al. Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 2005 90 : 2537 44.
22. Bottner A, Kratzsch J, Muller G, et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 2004 89 : 4053 61.
23. Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: Cross-sectional and interventional studies. J Clin Endocrinol Metab 2003 88 : 4823 31.
24. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: Stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003 49 : 650 2.
25. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999 130 : 883 90.
26. Festa A, D'Agostino R Jr., Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000 102 : 42 7.
27. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004 291 : 585 90.
28. Chak A, Faulx A, Eng C, et al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia. Cancer 2006 107 : 2160 6.
29. Buskens CJ, Hulscher JB, van Gulik TM, et al. Histopathologic evaluation of an animal model for Barrett's esophagus and adenocarcinoma of the distal esophagus. J Surg Res 2006 135 : 337 44.
30. Jeon J, Luebeck EG, Moolgavkar SH. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control 2006 17 : 971 81.
31. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant gene transcript 1). Biochem Biophys Res Commun 1996 221 : 286 9.
32. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: Evidence for participation of insulin resistance. Clin Cancer Res 2005 11 : 3642 6.
33. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 2005 97 : 1688 94.
34. Wang Y, Lam K, Xu J, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in oligomerization-dependent manner. J Biol Chem 2005 280 : 18341 7.
35. Wulster-Radcliffe MC, Ajuwon KM, Wang J, et al. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004 316 : 924 9.
36. Souza RF, Shewmake KL, Shen Y, et al. Differences in ERK activation in squamous mucosa in patients who have gastroesophageal reflux disease with and without Barrett's esophagus. Am J Gastroenterol 2005 100 : 551 9.
37. Lazar MA. How obesity causes diabetes: Not a tall tale. Science 2005 307 : 373 5.
38. Yokota T, Oritani K, Takahashi I, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000 96 : 1723 32.